AI Article Synopsis
- * A kidney biopsy showed signs of severe damage, including cast nephropathy and infiltration of B lymphocytes.
- * After receiving 6 cycles of a combination treatment (R-COP), his kidney function improved significantly, allowing him to stop hemodialysis; this is a rare case of successful treatment for WM-related kidney issues.
Article Abstract
A 60-year-old man with Waldenström's macroglobulinemia (WM) was admitted to our hospital for evaluation of rapid progressive renal deterioration despite 3 cycles of oral melphalan and prednisolone (MP) therapy. Renal biopsy just before introducing hemodialysis revealed cast nephropathy and severe tubulo-interstitial infiltration of B lymphocytes. After 6 cycles of rituximab, cyclophosphamide, vincristine and prednisolone (R-COP) therapy, his renal function improved enough to discontinue hemodialysis. This is a rare case of WM-related renal involvement caused by both monoclonal protein and tumor infiltration and, to our knowledge, the second report on improved renal function by rituximab-based therapy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2169/internalmedicine.51.7207 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Successful eculizumab treatment as an adjunctive therapy to desensitization in ABO-incompatible living donor kidney transplantation and its molecular phenotypes.
Front Immunol
November 2024
Department of Internal Medicine, College of Medicine, Yonsei University, Seoul, Republic of Korea.
Article Synopsis
- ABO-incompatible kidney transplantation (KT) is increasingly used to address organ shortages, but high levels of anti-ABO antibodies can hinder successful transplantation despite existing desensitization methods.
- Eculizumab was used as an additional treatment to help patients with very high anti-ABO antibodies who did not respond to standard therapies, showing improvements in kidney function and antibody levels after transplant.
- The study indicates that short-term eculizumab treatment may effectively support ABOi KT patients by maintaining stable kidney function and reducing antibody levels, even in cases previously deemed challenging.
Acquired hemophilia A (AHA) is an autoimmune bleeding disorder that is caused by factor VIII (FVIII) autoantibodies with high morbidity and mortality due to bleeding and complications from immunosuppression (IST). To address the real-world implications of the FVIII mimetic antibody, emicizumab, and the role of IST, we retrospectively collected de-identified data on 62 patients with AHA who were treated off-label with emicizumab for a median of 10 weeks at 12 US-based hemophilia treatment centers. Most patients (95.
View Article and Find Full Text PDFA Bruton tyrosine kinase inhibitor-resistance gene signature predicts prognosis and identifies TRIP13 as a potential therapeutic target in diffuse large B-cell lymphoma.
Sci Rep
September 2024
Department of Hematology/Hematological Lab, The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, People's Republic of China.
Article Synopsis
- * Researchers identified a 10-gene signature (including CARD16, TRIP13, and others) linked to BTKi resistance, allowing for early identification of high-risk DLBCL patients and improving prognosis predictions through a nomogram.
- * The key gene TRIP13 was overexpressed in both DLBCL and BTKi-resistant cell lines; reducing its levels decreased cell proliferation and enhanced the effects of BTKi, suggesting it could be a target for treatment in resistant
Low risk of hepatitis B virus reactivation in membranous nephropathy patients with resolved infection undergoing rituximab-based regimens without antiviral prophylaxis.
Int Immunopharmacol
September 2024
Department of Nephropathy, the First Affiliated Hospital of Zhengzhou University, No. 1 East Jianshe Road, Zhengzhou 450052, Henan, China. Electronic address:
Article Synopsis
- Patients with resolved hepatitis B virus infection undergoing rituximab for membranous nephropathy were studied to assess the risk of hepatitis B virus reactivation without antiviral prophylaxis.
- The study analyzed clinical data from 51 patients, tracking their treatment responses and any signs of virus reactivation during and after rituximab therapy.
- Results showed that 58.8% of patients achieved remission and none experienced hepatitis B reactivation during or after treatment, indicating a relatively low risk in this specific patient group.
First-line immunosuppressive therapies for acquired hemophilia A: A 25-year cohort experience and network meta-analysis.
Thromb Res
September 2024
Division of Hematology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand. Electronic address:
Acquired hemophilia A (AHA) presents a significant bleeding risk. Management involves bleeding control and immunosuppressive therapy (IST) to eliminate inhibitors. This study, encompassing a retrospective cohort of 76 newly diagnosed AHA patients (1997-2022), evaluated IST outcomes such as complete remission (CR), relapse, and mortality rates, alongside influencing factors.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!